

Silva Pharmaceuticals Limited


Statement of Financial Position

(Un-Audited)


As at 30 September, 2018

Particulars	Notes	Amount in Taka	
		30-Sep-18	30-Jun-18
ASSETS			
Non Current Assets		1,096,947,509	1,088,236,707
Property, Plant & Equipment	3.00	890,624,552	890,460,110
Capital work-in-Progress	4.00	206,322,957	197,776,597
Current Assets		1,541,449,895	913,520,356
Inventories	5.00	394,254,922	389,774,512
Trade and Other Receivables		261,881,841	249,791,383
Advances, Deposits and Prepayments		111,150,767	138,657,501
Investment in FDR		85,000,000	85,000,000
Cash and Cash Equivalents	6.00	689,162,365	50,296,960
Total Assets		2,638,397,404	2,001,757,063
SHAREHOLDERS EQUITY AND LIABILITIES:			
Equity attributable to the Shareholders		2,053,153,498	1,710,561,004
Share Capital	7.00	1,300,000,000	1,000,000,000
Retained Earnings	8.00	753,153,498	710,561,004
Non-Current Liabilities		65,568,198	91,219,792
Deferred Tax Liabilities		65,568,198	91,219,792
Current Liabilities		519,675,708	199,976,267
Trade and Other Payables		353,799,788	4,461,993
Current Portion of Long term Loan		99,000,000	99,000,000
Provision for Expenses		66,875,920	96,514,274
Total Liabilities		585,243,906	291,196,059
Total Equity & Liabilities:		2,638,397,404	2,001,757,063
Net Assets Value (NAV) per share	12.00	15.79	17.11

The annexed notes are form an integral part of these financial statements.



Chairman



Managing Director



Director



Chief Financial Officer



Company Secretary

Place: Dhaka;

Dated: November 13, 2018

Silva Pharmaceuticals Limited

Statements of Profit or Loss and other Comprehensive Income

(Un-Audited)

For the First Quarter ended 30 September, 2018

Particulars	Notes	Amount in Taka	
		July - September, 2018	July - September, 2017
Turnover		179,675,492	169,875,624
Cost of goods sold		(108,585,137)	(105,658,757)
Gross Profit		71,090,355	64,216,867
Operating expenses		(31,032,854)	(29,331,381)
Operating Income		40,057,501	34,885,486
Financial expenses		(3,354,061)	(26,215)
Net Operating Profit		36,703,440	34,859,271
Interest and Other income		1,510,066	2,523,705
Net Profit before Contribution to WPPF		38,213,506	37,382,976
Provision for Contribution to Worker's Profit Participation fund (WPPF)		(1,819,691)	(1,780,142)
Net Profit before Income Tax		36,393,815	35,602,834
Income Tax Expenses:		16,235,799	(12,661,738)
Current Tax Expenses		(9,415,795)	(11,649,639)
Deferred Tax expenses		25,651,594	(1,012,099)
Net Profit after tax		52,629,614	22,941,096
Basic Earnings Per Share (EPS)	11.00	0.48	0.23
Diluted Earnings Per Share (EPS)		0.48	0.21
Weighted Average Number of Shares		110,434,783	100,000,000

The annexed notes are form an integral part of these financial statements.


Chairman


Managing Director


Director


Chief Financial Officer


Company Secretary

Place: Dhaka;

Dated: November 13, 2018

Silva Pharmaceuticals Limited

Statement of Changes in Equity

(Un-Audited)

For the First Quarter ended 30 September, 2018

Particulars	<i>(Amount in Taka)</i>		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2018	1,000,000,000	710,561,004	1,710,561,004
Net profit after tax during the period	-	52,629,614	52,629,614
Issue of Share Capital	300,000,000	-	300,000,000
IPO Expenses Paid		(10,037,120)	(10,037,120)
Balance as at 30 September, 2018	1,300,000,000	753,153,498	2,053,153,498

For the First Quarter ended 30 September, 2017

Particulars	<i>(Amount in Taka)</i>		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2017	1,000,000,000	647,797,063	1,647,797,063
Net profit after tax during the period	-	22,941,096	22,941,096
Balance as at 30 September, 2017	1,000,000,000	670,738,159	1,670,738,159

The annexed notes form an integral part of these financial statements.


Chairman


Managing Director


Director


Chief Financial Officer


Company Secretary

Place: Dhaka;

Dated: November 13, 2018

Silva Pharmaceuticals Limited

Statement of Cash Flows


(Un-Audited)

For the First Quarter ended 30 September, 2018

Particulars	Amount in Taka	
	July - September, 2018	July - September, 2017
Cash flows from Operating Activities		
Cash received from Customers	167,313,158	161,319,661
Cash received from non-operating income	1,781,942	231,650
Cash Paid to Suppliers	(100,839,720)	(82,889,549)
Cash Paid to Employees	(33,809,871)	(24,530,256)
Cash Paid for Others	(6,464,922)	(10,224,500)
Income Tax Paid	(7,601,409)	(10,241,437)
Net cash inflow/(outflow) from operating activities (A)	20,379,178	33,665,569
Cash flows from Investing Activities		
Acquisition of Property, Plant and Equipment	(12,680,250)	(13,182,180)
Cash Payments for Capital Work-in-progress	(8,546,360)	(11,117,300)
Cash Payments for FDR	-	(7,500,000)
Net cash inflow/(outflow) from investing activities (B)	(21,226,610)	(31,799,480)
Cash flows from Financing Activities		
Long Term Loan received/(Repaid)	2,722,500	-
Cash payment for Financial Expenses	(3,185,316)	-
Cash payment for IPO Expenses	(10,037,120)	-
Share Application Money received	350,212,773	-
Issuance of Share Capital	300,000,000	-
Net cash inflow/(outflow) from financing activities (C)	639,712,837	-
Net increase/(decrease) of Cash and Cash Equivalents (A+B+C)	638,865,405	1,866,089
Cash and Cash Equivalents at the beginning of the period	50,296,960	83,509,106
Cash and Cash Equivalents at the end of the period	689,162,365	85,375,195
Net Operating Cash Flow Per Share	0.18	0.34

The annexed notes form an integral part of these financial statements.


Chairman


Managing Director


Director


Chief Financial Officer


Company Secretary

Place: Dhaka;

Dated: November 13, 2018